0001140361-23-040775.txt : 20230821
0001140361-23-040775.hdr.sgml : 20230821
20230821215914
ACCESSION NUMBER: 0001140361-23-040775
CONFORMED SUBMISSION TYPE: 144
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20230821
DATE AS OF CHANGE: 20230821
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Roivant Sciences Ltd.
CENTRAL INDEX KEY: 0001635088
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981173944
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
FILING VALUES:
FORM TYPE: 144
SEC ACT: 1933 Act
SEC FILE NUMBER: 001-40782
FILM NUMBER: 231190891
BUSINESS ADDRESS:
STREET 1: CLARENDON HOUSE, 2 CHURCH STREET
CITY: HAMILTON HM11
STATE: D0
ZIP: HM11
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: CLARENDON HOUSE
STREET 2: 2 CHURCH STREET
CITY: HAMILTON
STATE: D0
ZIP: HM11
REPORTING-OWNER:
COMPANY DATA:
COMPANY CONFORMED NAME: Gline Matthew
CENTRAL INDEX KEY: 0001750094
FILING VALUES:
FORM TYPE: 144
MAIL ADDRESS:
STREET 1: C/O UROVANT SCIENCES, INC.
STREET 2: 5151 CALIFORNIA AVENUE, SUITE 250
CITY: IRVINE
STATE: CA
ZIP: 92617
144
1
primary_doc.xml
144
0001750094
XXXXXXXX
LIVE
0001635088
Roivant Sciences Ltd.
001-40782
7th Floor
50 Broadway
London
X0
SW1H 0DB
44-207 400 3347
Gline Matthew
Director
CEO
Common shares, $0.0000000341740141 par value per share ("Common Shares")
E*TRADE FINANCIAL CORPORATION
3 EDISON DRIVE
ALPHARETTA
GA
30005
19792
215139.04
771742197
08/21/2023
NASDAQ
Common Shares
08/20/2023
Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan
Roivant Sciences Ltd.
N
19792
08/20/2023
N/A
N
Matthew Gline
c/o Roivant Sciences Ltd.
7th Floor, 50 Broadway
London
X0
SW1H 0DB
Common Shares
05/23/2023
18972
181751.76
Matthew Gline
c/o Roivant Sciences Ltd.
7th Floor, 50 Broadway
London
X0
SW1H 0DB
Common Shares
05/31/2023
30266
275117.94
Matthew Gline
c/o Roivant Sciences Ltd.
7th Floor, 50 Broadway
London
X0
SW1H 0DB
Common Shares
06/22/2023
10863
108738.63
Matthew Gline
c/o Roivant Sciences Ltd.
7th Floor, 50 Broadway
London
X0
SW1H 0DB
Common Shares
07/24/2023
11146
122494.54
Matthew Gline
c/o Roivant Sciences Ltd.
7th Floor, 50 Broadway
London
X0
SW1H 0DB
Common Shares
07/31/2023
11749
138520.71
The securities included in Table I represent a maximum number of shares that may be sold to cover the reporting person's tax obligations when capped value appreciation rights belonging to the reporting person are settled. The securities included in Table II represent shares sold to cover the reporting person's tax obligations when restricted stock units or capped value appreciation rights belonging to the reporting person were settled. Table II does not include shares that were "net settled" by the Issuer in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units or capped value appreciation rights previously granted to the reporting person. The securities reported in Tables I and II do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations.
08/21/2023
02/22/2022
/s/ Matthew Gline